See more : Kato Sangyo Co., Ltd. (9869.T) Income Statement Analysis – Financial Results
Complete financial analysis of CBD Life Sciences Inc. (CBDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CBD Life Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Kelsian Group Limited (KLS.AX) Income Statement Analysis – Financial Results
- ViewCast.com, Inc. (VCST) Income Statement Analysis – Financial Results
- YTL Corporation Berhad (4677.KL) Income Statement Analysis – Financial Results
- United Royale Holdings Corp. (URYL) Income Statement Analysis – Financial Results
- Deutsche Wohnen SE (DTCWY) Income Statement Analysis – Financial Results
CBD Life Sciences Inc. (CBDL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://lbcbioscienceinc.com
About CBD Life Sciences Inc.
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company is based in Scottsdale, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167.15K | 160.24K | 59.26K | 225.90K | 79.64K | 122.79K | 155.55K | 0.00 | 0.00 |
| Cost of Revenue | 197.75K | 440.50K | 207.51K | 438.13K | 43.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.60K | -280.26K | -148.25K | -212.23K | 36.63K | 122.79K | 155.55K | 0.00 | 0.00 |
| Gross Profit Ratio | -18.31% | -174.90% | -250.18% | -93.95% | 46.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.20K | 0.00 | 1.39K | 314.85 | 337.43 | 752.49K | 442.90K | 53.29K | 44.12K |
| Selling & Marketing | 11.34K | 0.00 | 4.41K | 30.00 | 111.54 | 108.00K | 17.48K | 6.46K | 8.02K |
| SG&A | 46.05K | 571.77K | 4.96M | 171.86K | 906.25K | 860.49K | 460.38K | 59.75K | 52.14K |
| Other Expenses | 0.00 | -7.78K | -17.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 47.97K | 579.55K | 4.98M | 171.86K | 906.25K | 883.80K | 499.04K | 155.72K | 52.74K |
| Cost & Expenses | 245.72K | 1.02M | 5.19M | 609.99K | 949.26K | 883.80K | 499.04K | 155.72K | 52.74K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 69.91K | 0.00 | 15.27K | 23.50K | 0.00 | 0.00 |
| Depreciation & Amortization | 55.56K | 53.56K | 236.56K | 206.30K | 171.86K | 23.31K | 38.66K | 95.97K | 0.00 |
| EBITDA | -23.02K | -806.25K | -5.13M | -1.31M | -869.62K | -741.56K | -304.97K | -60.36K | -52.74K |
| EBITDA Ratio | -13.77% | -503.14% | -8,654.23% | -170.03% | -1,092.01% | -600.79% | -195.96% | 0.00% | 0.00% |
| Operating Income | -78.57K | -859.80K | -5.13M | -384.09K | -869.62K | -780.14K | -367.14K | -156.33K | -52.74K |
| Operating Income Ratio | -47.01% | -536.57% | -8,654.23% | -170.03% | -1,092.01% | -635.35% | -236.02% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -4.00 | -2.00 | -1.31M | 8.61K | -15.27K | -23.50K | 0.00 | 0.00 |
| Income Before Tax | -78.57K | -859.80K | -5.13M | -1.69M | -861.01K | -780.14K | -367.14K | -156.33K | -52.74K |
| Income Before Tax Ratio | -47.01% | -536.57% | -8,654.24% | -750.07% | -1,081.20% | -635.35% | -236.02% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 | -6.14K | -384.09 | -75.24 | 15.27K | 23.50K | 610.00 | 0.00 |
| Net Income | -78.57K | -859.80K | -5.13M | -1.69M | -861.01K | -780.14K | -367.14K | -156.33K | -52.74K |
| Net Income Ratio | -47.01% | -536.57% | -8,654.24% | -750.07% | -1,081.20% | -635.35% | -236.02% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -428.18 | -2.29K | -2.41K | -893.95 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -428.18 | -2.29K | -2.41K | -893.95 |
| Weighted Avg Shares Out | 40.71B | 40.71B | 12.30B | 934.78M | 108.36M | 1.82K | 160.00 | 65.00 | 59.00 |
| Weighted Avg Shares Out (Dil) | 40.71B | 40.71B | 12.30B | 934.78M | 108.36M | 1.82K | 160.00 | 65.00 | 59.00 |
CBD Life Sciences Provides Update on Exciting Future Following Completion of Reverse Split; Company Poised to Launch Rebranded CBD Products and Online Presence
SCOTTSDALE, AZ / ACCESSWIRE / April 23, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL), today provided a corporate update, in the wake of its recent reverse split, that focuses on the long-planned rebranding of its CBD products and launch...
CBD Life Sciences, Inc. (CBDL) Set to Present at ERRL Cup Cannabis Event
SCOTTSDALE, AZ / ACCESSWIRE / March 10, 2022 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces today that the company is going to be all set up and ready to go for...
CBD Life Sciences, Inc. (CBDL) Debuts Kratom for Treatment of Pain and Opioid Withdrawal
SCOTTSDALE, AZ / ACCESSWIRE / October 13, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding its product line with Kratom, which is an outstanding...
CBD Life Sciences, Inc. (CBDL) Launches on eBay Featuring Hemp Skincare Line
SCOTTSDALE, AZ / ACCESSWIRE / September 29, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding in B2B e-commerce through eBay and will be launching...
CBD Life Sciences, Inc. (CBDL) Announces Significant Increase in CBD Production Following Inventory Demand Through Online Sales
SCOTTSDALE, AZ / ACCESSWIRE / September 14, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company has begun to substantially increase its rate of production of CBD-based products in...
CBD Life Sciences, Inc. (CBDL) Set To Expand Its E-Commerce Through Alibaba.com Platform
SCOTTSDALE, AZ / ACCESSWIRE / September 8, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is expecting to launch its products onto the Alibaba Platform by early October....
CBD Life Sciences, Inc. (CBDL) Applies for Agricultural Hemp License in Arizona
SCOTTSDALE, AZ / ACCESSWIRE / August 30, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is applying for the Agricultural Hemp License in Arizona! CBD Life Sciences Inc....
CBD Life Sciences, Inc. (CBDL) Set to Present at the White Label Expo in Las Vegas
SCOTTSDALE, AZ / ACCESSWIRE / August 18, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is set to present at the White Label Expo in Las Vegas from...
CBD Life Sciences, Inc. (CBDL) Debuts Vegan Non-GMO Gluten Free Gummies
SCOTTSDALE, AZ / ACCESSWIRE / August 4, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding its product line with all new Vegan, non-GMO Gluten...
CBD Life Sciences, Inc. (CBDL) Debuts Delta-10 Cartridges
SCOTTSDALE, AZ / ACCESSWIRE / July 21, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding its product line with all-new Delta-10 Cartridges. CBD Life...
Source: https://incomestatements.info
Category: Stock Reports